Apixaban Dosing and Administration
For atrial fibrillation, prescribe apixaban 5 mg twice daily as the standard dose, reducing to 2.5 mg twice daily ONLY when patients meet at least TWO of three specific criteria: age ≥80 years, body weight ≤60 kg, OR serum creatinine ≥1.5 mg/dL. 111
Standard Dosing by Indication
Atrial Fibrillation (Stroke Prevention)
- Standard dose: 5 mg orally twice daily
- Reduced dose: 2.5 mg twice daily when ≥2 criteria present:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL (133 μmol/L)
The requirement for TWO criteria is critical—this is the most commonly violated dosing rule in clinical practice. 111 Studies show that 61% of patients receiving reduced-dose apixaban do not actually meet criteria for dose reduction, representing inappropriate underdosing. 23
VTE Treatment (DVT/PE)
- Initial 7 days: 10 mg twice daily
- After 7 days: 5 mg twice daily
- Extended prophylaxis: 2.5 mg twice daily (after completing ≥6 months of treatment) 11
Post-Surgical VTE Prophylaxis
- Dose: 2.5 mg twice daily
- Timing: Start 12-24 hours post-surgery
- Duration: 35 days (hip replacement) or 12 days (knee replacement) 11
Renal Impairment Adjustments
For atrial fibrillation patients:
- CrCl >50 mL/min: Use standard dosing algorithm (5 mg or 2.5 mg based on the two-criteria rule)
- CrCl 15-50 mL/min: Serum creatinine ≥1.5 mg/dL counts as ONE criterion toward dose reduction 45
- CrCl <15 mL/min or dialysis: Use 5 mg twice daily, reduce to 2.5 mg twice daily if age ≥80 years OR body weight ≤60 kg 465
Recent evidence from patients with severe CKD (stage 4/5) demonstrates that 5 mg apixaban increases bleeding risk compared to 2.5 mg (subdistribution HR 1.63,95% CI 1.04-2.54) without reducing stroke risk, supporting more conservative dosing in advanced renal disease. 7
For VTE treatment: No dose adjustment recommended regardless of renal function 1
Hepatic Impairment
No dose adjustment required for mild-to-moderate hepatic impairment (Child-Pugh A or B). Pharmacokinetic studies show minimal impact on drug exposure or anticoagulant effect. 8 Apixaban is not recommended in severe hepatic impairment. 4
Drug Interactions Requiring Dose Adjustment
When combined P-gp and strong CYP3A4 inhibitors are used (ketoconazole, itraconazole, ritonavir, clarithromycin):
- If taking 5 mg or 10 mg twice daily: Reduce dose by 50%
- If already taking 2.5 mg twice daily: Avoid concomitant use 114
Avoid apixaban entirely with strong dual P-gp/CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) as they significantly reduce apixaban levels. 4
Perioperative Management
High bleeding risk procedures:
- Stop apixaban 48 hours before surgery (skip 4 doses for twice-daily dosing)
- CrCl 30-50 mL/min: Stop 4-5 days before (skip 6-8 doses) 911
Low bleeding risk procedures:
Bridging anticoagulation is not generally required during the 24-48 hour interruption period. 11
Switching Between Anticoagulants
From warfarin to apixaban: Discontinue warfarin and start apixaban when INR <2.0 11
From apixaban to warfarin: Discontinue apixaban and begin both parenteral anticoagulant and warfarin simultaneously at the time of next apixaban dose; stop parenteral agent when INR therapeutic 11
Between apixaban and other DOACs/parenteral agents: Simply switch at the time of the next scheduled dose 11
Critical Pitfalls to Avoid
The single-criterion error: The most common prescribing mistake is reducing apixaban to 2.5 mg twice daily when only ONE criterion is present (especially age ≥80 years alone or low body weight alone). This results in underdosing and potentially inadequate stroke protection. 210 Apixaban shows the highest rates of inappropriate dosing among DOACs, with underdosing occurring in 9.4-40.4% of prescriptions. 2
The bleeding risk trap: Do NOT reduce apixaban dose based solely on perceived bleeding risk, history of bleeding, or HAS-BLED score. These are NOT FDA-approved dose reduction criteria. 211 While European guidelines suggest considering 110 mg dabigatran for high bleeding risk, no such recommendation exists for apixaban dose reduction beyond the specified criteria. 11
End-stage renal disease confusion: Unlike other DOACs, apixaban can be used in dialysis patients. Use 5 mg twice daily unless age ≥80 years OR weight ≤60 kg (then use 2.5 mg twice daily). 465
Concomitant antiplatelet therapy: When starting apixaban for atrial fibrillation, antiplatelet agents should generally be discontinued unless there is a specific indication (recent PCI/ACS). The combination significantly increases bleeding risk. 1213
Administration Considerations
- Can be taken with or without food (except rivaroxaban, which requires food)
- For patients unable to swallow: 5 mg and 2.5 mg tablets may be crushed and mixed with water, apple juice, or applesauce and administered immediately 1
- If dose missed: Take as soon as remembered on the same day; resume twice-daily schedule. Never double the dose 11